Efficacy of Rabeprazole Combined with Amoxicillin or Furazolidone Dual Therapy in Eradicating Helicobacter pylori Infection

Background Helicobacter pylori (H.pylori) infection is strongly associated with peptic ulcer, gastric cancer, gastric lymphoma, and other diseases. A new dual therapy has proven effective in the eradication of H.pylori, but it has not been verified in some areas with a high prevalence of H.pylori infection in central China. Objective To explore the clinical efficacy of rabeprazole combined with amoxicillin or furazolidone dual therapy in the eradication of H.pylori infection. Methods 161 patients with a first diagnosis of H.pylori infection were recruited from Department of Gastroenterology, Henan Provincial People's Hospital during April 2020 to October 2021, and randomized into three groups with different 14-day therapies: group A (n=55) received a twice-daily quadruple therapy consisting of rabeprazole (20 mg) + bismuth potassium citrate (220 mg) + amoxicillin (1 000 mg) + furazolidone (100 mg) , group B (n=54) received a three-time daily dual therapy consisting of rabeprazole (20 mg) + high-dose amoxicillin (1 000 mg) , and group C (n=52) received a three-time daily dual therapy consisting of rabeprazole (20 mg) + high-dose furazolidone (100 mg) . The eradication rate, side effects and cost-effectiveness ratio were compared among the groups. Results Intention-to-treat analysis (ITT) revealed that, the eradication rates of H.pylori in groups A, B and C were 83.6% (46/55) , 81.5% (44/54) and 48.1% (25/52) , respectively. Per-protocol (PP) analysis found that, the eradication rates of H.pylori in groups A, B and C were 88.5% (46/52) , 83.0% (44/53) and 51.0% (25/49) , respectively. Both analyses demonstrated that groups A, B had higher eradication rates of H.pylori than group C (P